NeoGenomics Laboratories Inc. has contested Natera Inc.’s attempt to withdraw its jury trial demand in a patent infringement case concerning DNA cancer test technology. NeoGenomics argues that Natera lacks the right to unilaterally opt for a bench trial, emphasizing the importance of a jury’s role in such complex patent disputes.
This legal confrontation is part of a broader series of disputes between the two companies. In July 2023, Natera filed a lawsuit against NeoGenomics, alleging that its RaDaR molecular residual disease assay infringed on Natera’s U.S. Patent Nos. 11,519,035 and 11,530,454. The patents pertain to methods for amplifying and sequencing DNA, particularly in detecting variations indicative of disease recurrence. Natera’s complaint asserts that NeoGenomics’ RaDaR test unlawfully utilizes these patented methods.
In December 2023, the U.S. District Court for the Middle District of North Carolina granted Natera a preliminary injunction, effectively barring NeoGenomics from making, using, selling, or promoting its RaDaR assay in the United States, with limited exceptions. The court’s decision underscored the potential validity of Natera’s claims and the likelihood of irreparable harm if the alleged infringement continued.
Subsequently, in September 2024, the court issued a permanent injunction against NeoGenomics’ RaDaR assay, further solidifying Natera’s position in the ongoing litigation. This permanent injunction indicates the court’s determination that NeoGenomics’ product infringes upon Natera’s patents and that continued use would cause significant harm to Natera’s business interests.
NeoGenomics’ insistence on a jury trial reflects a strategic approach to the litigation process. Jury trials in patent cases can be advantageous for defendants, as jurors may be more receptive to arguments challenging the validity of patents or the extent of alleged infringement. Conversely, bench trials, decided solely by a judge, might favor plaintiffs who can present complex technical arguments more effectively to a legally trained audience.
The outcome of this dispute could have significant implications for both companies and the broader genetic testing industry. A ruling in favor of Natera may reinforce the strength of its patent portfolio and deter potential infringers, while a decision favoring NeoGenomics could encourage more aggressive competition and innovation within the sector.
As the case progresses, stakeholders in the genetic testing field will be closely monitoring developments, recognizing that the resolution may set important precedents for patent enforcement and the balance between protecting intellectual property and fostering innovation.